➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Johnson and Johnson
Boehringer Ingelheim
AstraZeneca
Dow

Last Updated: September 16, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DALBAVANCIN HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Dalbavancin Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00057369 ↗ Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections Unknown status Vicuron Pharmaceuticals Phase 2 2001-02-01 This is a study to evaluate a new medication dosed once a week in the treatment of bacterial infections in the blood from intravenous catheters (CR-BSI). The primary objective is to evaluate the efficacy and safety of dalbavancin in the treatment of adults with CR-BSI relative to a standard of care treatment, vancomycin.
NCT00678106 ↗ Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections Completed Pfizer Phase 1 2008-09-01 Adolescent subjects hospitalized for the treatment of bacterial infections will be given 1 gram of dalbavancin through their veins and levels of dalbavancin in blood and urine will be measured at different time points. Safety labs will also be checked on a regular basis to assess the safety of dalbavancin.
NCT01339091 ↗ Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Completed Durata Therapeutics Inc., an affiliate of Allergan plc Phase 3 2011-03-01 The primary object is to compare the early clinical efficacy (after 48-72 hours of therapy) of dalbavancin to the comparator regimen (vancomycin with the option to switch to oral linezolid) for the treatment of patients with a suspected or proven gram-positive bacterial skin or skin structure infection.
NCT01431339 ↗ Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Completed Durata Therapeutics Inc., an affiliate of Allergan plc Phase 3 2011-07-01 The primary object is to compare the early clinical efficacy (after 48-72 hours of therapy) of dalbavancin to the comparator regimen (vancomycin with the option to switch to oral linezolid) for the treatment of patients with a suspected or proved gram-positive bacterial skin or skin structure infections.
NCT01946568 ↗ A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years. Completed Durata Therapeutics Inc., an affiliate of Allergan plc Phase 1 2013-06-01 A phase one study to characterize the pharmacokinetics of dalbavancin in pediatric patients aged 3 months to 11 years (inclusive) following the intravenous administration of a single dose of dalbavancin.
NCT02127970 ↗ Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Completed Durata Therapeutics Inc., an affiliate of Allergan plc Phase 3 2014-04-01 To compare the efficacy of treatment with a single dose of dalbavancin 1500 mg to treatment with a two dose regimen of dalbavancin (1000 mg on Day 1 followed by 500 mg on Day 8) in patients with known or suspected Gram-positive abSSSI (acute bacterial skin and skin structure infections) at 48 -72 hours after initiation of treatment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Dalbavancin Hydrochloride

Condition Name

Condition Name for Dalbavancin Hydrochloride
Intervention Trials
Bacterial Infections 5
Osteomyelitis 4
Cellulitis 3
Abscess 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Dalbavancin Hydrochloride
Intervention Trials
Infection 13
Communicable Diseases 12
Bacterial Infections 8
Bacteremia 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Dalbavancin Hydrochloride

Trials by Country

Trials by Country for Dalbavancin Hydrochloride
Location Trials
United States 98
South Africa 8
Russian Federation 7
Ukraine 4
Estonia 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Dalbavancin Hydrochloride
Location Trials
California 8
Florida 7
Louisiana 6
New York 6
Michigan 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Dalbavancin Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Dalbavancin Hydrochloride
Clinical Trial Phase Trials
Phase 4 4
Phase 3 6
Phase 2/Phase 3 1
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Dalbavancin Hydrochloride
Clinical Trial Phase Trials
Not yet recruiting 8
Completed 5
Recruiting 5
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Dalbavancin Hydrochloride

Sponsor Name

Sponsor Name for Dalbavancin Hydrochloride
Sponsor Trials
Durata Therapeutics Inc., an affiliate of Allergan plc 8
Allergan 5
University of Colorado, Denver 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Dalbavancin Hydrochloride
Sponsor Trials
Industry 16
Other 5
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Colorcon
AstraZeneca
Express Scripts
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.